Prostate Cancer
Conditions
Interventions
Cohort A(high dose boost group):The entire prostatic region ± seminal vesicles
70Gy/25f
EQD2 = 81.2 Gy
IDN
6-8Gy/1f
(or simultaneous boost to 72.5-75Gy/25f)
EQD2=92-98.8 (85.6-90) Gy
Cohort B (moderate and low dose boost group) :The entire prostatic region ± seminal vesicles
67.5-70Gy/25f
EQD2=77-81.2Gy
IDN
5Gy/1f
(or simultaneous boost to72.5Gy/25f)
EQD2=85-89.2(85.6)Gy
Cohort C (elderly patient group) :The entire prostatic region ± seminal vesicles
65Gy/25f
EQD2=72.8Gy
IDN
70Gy/25f
EQD2=81.2Gy
Cohort D (standard dose group):The entire prostatic region ± seminal vesicles
70Gy/25f
EQD2=81.2Gy
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 95 Years
Inclusion criteria
Inclusion criteria: Overall inclusion criteria: Patients with prostate cancer admitted to Peking University First Hospital who met the admission criteria and met the following criteria: 1. Prostate cancer diagnosed by biopsy, staging cT1-4N0-1M0; 2. Body imaging (such as bone scan or PET-CT) excluding distant metastases; 3. Expected survival greater than 12 months; 4. Age >18 years old; 5. KPS>70 points; 6. White blood cells =3.0×109/l, neutrophils =1.5×109/l, platelets =75.0×109/l, hemoglobin =90g/l; 7. Patients give informed consent and sign informed consent. Unit inclusion criteria: Cohort A (high dose boost group) : Prostate biopsy found Gleason Score to contain 5 components, or age =50 years. Cohort B (moderate and low dose boost group) : Prostate biopsy was performed with Gleason Score 6-8 without 5-point component. Cohort C (elderly patient group) : =80 years of age with poor radiotherapy tolerance as assessed by the physician in charge. Cohort D (standard dose group) : No distinction was made between prostate and tumor area dose patients.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1. Patietn who have a history of malignant tumors (except skin cancer with non-malignant melanoma and tumors that have been cured for more than 5 years); 2. Had received abdominal pelvic radiotherapy; 3. Those with existing or combined severe hemorrhagic disease; 4. There are clinically uncontrolled comorbiditions, such as toxic shock from infection, drug-uncontrolled hypertension, uncontrolled unstable angina, New York Heart Association (NYHA) =II congestive heart failure, unstable symptomatic arrhythmia, etc. 5. Those without informed consent due to psychological, family, social and other factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-free survival,EFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Distance metastasis free survival,DMFS;Overall survival, OS;Side effects and quality of life; | — |
Countries
China
Contacts
Public ContactMing-Wei Ma
Peking University First Hospital
Outcome results
None listed